Clinical trials: R-CHOP Chemotherapy
Lymphoma, Large B-Cell, Diffuse
A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma
This multicenter, randomized, open label parallel-group study will evaluate the efficacy and safety of subcutaneous versus intravenous MabThera/Rituxan (rituximab) in combination with CHOP chemotherapy in patients with previously…
- Trial name
- NCT01649856
- Testing
- CHOP, rituximab [MabThera/Rituxan]
- Where
- 186 sites in Algeria, Argentina and 25 more
- Volunteers
- 572 people
- Sponsor
- Hoffmann-La Roche
Diffuse Large B-Cell Lymphoma
An Observational Study of MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in First-Line in Patients With Diffuse Large B-Cell Lymphoma
This multicenter, observational study will evaluate the correlation between clinical and biological factors and International Prognostic Index (IPI) as prognostic factors in patients with diffuse large B-cell lymphoma receiving…
- Trial name
- NCT01724294
- Where
- Romania
- Volunteers
- 113 people
- Sponsor
- Hoffmann-La Roche
Lymphoma
Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma
RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, can block cancer cells in different ways.
- Trial name
- NCT01334502
- Testing
- rituximab, cyclophosphamide, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Chronic Lymphocytic Leukemia
Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia (CLL) That Did Not Respond to Fludarabine, CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT)
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00309881
- Testing
- rituximab, cyclophosphamide, doxorubicin hydrochloride
- Where
- 18 sites in Germany
- Volunteers
- 75 people
- Sponsor
- German CLL Study Group
Lymphoma
Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma
RATIONALE: Monoclonal antibodies such as rituximab and yttrium Y 90 ibritumomab tiuxetan can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00058422
- Testing
- darbepoetin alfa, filgrastim, rituximab
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lymphoma, Mantle-Cell
Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL
The aim of this study is to answer the following independent questions in the treatment of mantle cell lymphomas: Can rituximab-fludarabine, cyclophosphamide (R-FC) improve the reduction of lymphoma mass compared to…
- Trial name
- MCLelderly (NCT00209209)
- Testing
- Rituximab, Cyclophosphamide, Doxorubicin
- Where
- 7 sites in Czechia, Denmark and 5 more
- Volunteers
- 570 people
- Sponsor
- European Mantle Cell Lymphoma Network
Lymphoma, Large B-Cell, Diffuse
A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib
The aims of this study are: To evaluate the benefits of the addition of bortezomib to standard rituximab with cyclophosphamide, doxorubicin, vincristine, prednisolone (R-CHOP) therapy in Diffuse Large B-cell Lymphoma (DLBCL).
- Trial name
- REMoDL-B (NCT01324596)
- Testing
- Intravenous, Bortezomib
- Where
- 109 sites in Switzerland, United Kingdom
- Volunteers
- 1,132 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type
Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma
The purpose of this research study is to evaluate a new investigational drug, TAK-659, given in combination with standard chemotherapy, for the treatment of Diffuse Large B-cell Lymphoma (DLBCL).
- Conditions
- Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Trial name
- NCT03742258
- Testing
- Cyclophosphamide, Doxorubicin Hydrochloride, Prednisone
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Northwestern University
Large B Cell Lymphoma
Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
This randomized phase III trial studies rituximab when given together with two different combination chemotherapy regimens to compare how well they work in treating patients with diffuse large B-cell non-Hodgkin's lymphoma.
- Trial name
- NCT00118209
- Testing
- rituximab, cyclophosphamide, doxorubicin
- Where
- 47 sites in United States
- Volunteers
- 524 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Diffuse Large B-cell Lymphoma (DLBCL)
Intensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL)
The purpose of this study is to evaluate the complete response (CR) rate after Intensified 1st cycle Rituximab plus 3rd cycles of R-CHOP in DLBCL
- Trial name
- NCT01054781
- Testing
- Rituximab
- Where
- South Korea
- Volunteers
- 91 people
- Sponsor
- Samsung Medical Center
Non-Hodgkin's Lymphoma
Pegfilgrastim Administered on the Same Day as Chemotherapy in Non-Hodgkin's Lymphoma
The purpose of this study is to provide data on the safety and efficacy of pegfilgrastim when administered on the same day versus the next day of chemotherapy, as measured by the duration of grade 4 neutropenia.
- Trial name
- NCT00115193
- Testing
- pegfilgrastim
- Volunteers
- 77 people
- Sponsor
- Amgen
Aggressive Non-Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma
Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma
This phase I/II trial studies the side effects and best dose of nivolumab and how well it works when giving together with combination chemotherapy in treating participants with diffuse large B-cell lymphoma.
- Conditions
- Aggressive Non-Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, CD20 Positive, Diffuse Large B-Cell Lymphoma Unclassifiable
- Trial name
- NCT03704714
- Testing
- Cyclophosphamide, Doxorubicin Hydrochloride, Nivolumab
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Northwestern University
Mantle Cell Lymphoma Refractory
Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL).
This is a multicenter, open label, three arms, Phase IB study. A dose escalation phase of Temsirolimus (Torisel™) administered in intravenous (IV) at day 2, day 8 and day 15 in combination with three chemotherapies regimens for…
- Trial name
- T³ (NCT01389427)
- Testing
- Torisel dose 15 mg and R-CHOP, Torisel dose 15 mg and R-FC, Torisel dose 15 mg and R-DHA
- Where
- 11 sites in France
- Volunteers
- 41 people
- Sponsor
- The Lymphoma Academic Research Organisation
Diffuse Large B Cell Lymphoma
Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients
It is expected that addition of anti-CD20 antibody - ofatumumab would enhance the activity of the etoposide+ifosphamide with mesna+cytarabine+methotrexate+lenograstim or filgrastim (IVAC) regimen.
- Trial name
- PLRG8 (NCT01481272)
- Testing
- Ofatumumab, Etoposide, Ifosfamid
- Where
- 8 sites in Poland
- Volunteers
- 77 people
- Sponsor
- Polish Lymphoma Research Group
B-cell Lymphoma
A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma
This 2-arm study was designed to compare the efficacy and safety of bevacizumab (Avastin) in combination with rituximab (MabThera) and CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone)…
- Trial name
- NCT00486759
- Testing
- Bevacizumab, Rituximab, CHOP
- Where
- 266 sites in United States, Argentina and 32 more
- Volunteers
- 787 people
- Sponsor
- Hoffmann-La Roche
Non-Hodgkin's Lymphoma
Treatment for Subjects With Non-Hodgkin's Lymphoma
This multicenter, open-label, randomized, parallel study was designed to evaluate whether a single fixed-dose subcutaneous (SC) administration of pegfilgrastim or daily administration of Filgrastim for absolute neutrophil count…
- Trial name
- NCT00117897
- Testing
- pegfilgrastim, Filgrastim
- Sponsor
- Amgen
Lymphoma
Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients
The goal of this clinical research study is to learn the effect of combining aprepitant with CHOP or R-CHOP in patients with Non-Hodgkin's Lymphoma (NHL) that is either newly diagnosed or has come back.
- Trial name
- NCT00651755
- Testing
- Aprepitant, Cyclophosphamide, Doxorubicin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- M.D. Anderson Cancer Center
Mantle Cell Lymphoma
Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma
This is a multicenter, open-label, non-randomized, phase II clinical trial conducted in Canada. The purpose of the study is to determine the remission rate of acalabrutinib in combination with R-CHOP in patients with previously…
- Trial name
- NCT04566887
- Testing
- Acalabrutinib, R-CHOP chemotherapy
- Where
- 5 sites in Canada
- Volunteers
- 105 people
- Sponsor
- University Health Network, Toronto
Lymphoma
Treatment of Disseminated High Grade Lymphoma
Interest of the use of pegylated liposomal doxorubicin (caélyx)
- Trial name
- NCT00536393
- Testing
- Doxorubicin, Doxorubicin pegylated
- Where
- France
- Volunteers
- 100 people
- Sponsor
- French Innovative Leukemia Organisation
Large B-cell Lymphoma
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
The purpose of this study is to compare the effectiveness and safety of golcadomide in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy vs placebo in combination with…
- Trial name
- GOLSEEK-1 (NCT06356129)
- Testing
- Golcadomide, Rituximab, Cyclophosphamide
- Where
- 325 sites in United States, Argentina and 36 more
- Volunteers
- 850 people
- Sponsor
- Celgene